Therefore, the addition of a PDGFRβ inhibitor to existing targeted agents could potentially aid in obtaining a durable response in the clinic and should be considered in future clinical trial evaluations of combination-targeted therapy across multiple cancers. The gene discussed is PDGFRB; the disease is cancer.